Results 101 to 110 of about 455 (134)
Patients' perspective on allergen immunotherapy for respiratory allergy. [PDF]
Curr Opin Allergy Clin ImmunolCatamerò F +4 more
europepmc +1 more source
A retrospective analysis of factors influencing response to omalizumab treatment in Indian patients with antihistamine refractory chronic spontaneous urticaria. [PDF]
Asia Pac AllergyPrarthana T +4 more
europepmc +1 more source
The Predictive Value of Serum Total IgE for Antihistamine Treatment Outcomes in Chinese Patients with Chronic Spontaneous Urticaria. [PDF]
Acta Derm VenereolLi Y, Peng R, Xue J, Zhao Y.
europepmc +1 more source
Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes. [PDF]
Acta Derm VenereolPesqué D +6 more
europepmc +1 more source
Sustained control of recalcitrant chronic spontaneous urticaria after initiation of inflammatory airway diseases treatment: two case reports. [PDF]
J Med Case RepNguyen D, Deitiker P.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Indian Journal of Skin Allergy, 2022
Objectives: In patients not responding to standard dosages of second-generation antihistamines (SGAHs), updosing up to 4-fold is recommended. Even though SGAHs are safe, the concerns regarding their safety after updosing still remain and the studies directly comparing the updosing of different SGAHs are lacking thus making the choice of drug difficult.
Deval Mistry, Bela Shāh
exaly +2 more sources
Objectives: In patients not responding to standard dosages of second-generation antihistamines (SGAHs), updosing up to 4-fold is recommended. Even though SGAHs are safe, the concerns regarding their safety after updosing still remain and the studies directly comparing the updosing of different SGAHs are lacking thus making the choice of drug difficult.
Deval Mistry, Bela Shāh
exaly +2 more sources
Journal of Cutaneous Medicine and Surgery, 2019
Background: Omalizumab is a third-line treatment for chronic spontaneous urticaria (CSU). Studies investigating the use of higher doses of omalizumab in patients unresponsive to regular doses are limited. Objectives: This study aims to
Andac Salman
exaly +4 more sources
Background: Omalizumab is a third-line treatment for chronic spontaneous urticaria (CSU). Studies investigating the use of higher doses of omalizumab in patients unresponsive to regular doses are limited. Objectives: This study aims to
Andac Salman
exaly +4 more sources
British Journal of Dermatology, 2016
There is a lack of large, randomized, double-blind studies that address antihistamine updosing for chronic spontaneous urticaria (CSU). The objective of this systematic review is to explore and analyse available data to provide clinical evidence for the efficacy of antihistamine updosing.
Marta Ferrer, FRANCISCO Guillén-Grima
exaly +3 more sources
There is a lack of large, randomized, double-blind studies that address antihistamine updosing for chronic spontaneous urticaria (CSU). The objective of this systematic review is to explore and analyse available data to provide clinical evidence for the efficacy of antihistamine updosing.
Marta Ferrer, FRANCISCO Guillén-Grima
exaly +3 more sources
Updosing antihistamines in chronic spontaneous urticaria
Geneesmiddelenbulletin, 2022Ca Van Den Bogert
exaly +2 more sources